FDA Approves New Breast Implant

January 25, 2017

Earlier this month, the U.S. Food and Drug Administration (FDA) approved Allergan’s Natrelle Inspira SoftTouch breast implants, which provide a medium-firm gel option for women undergoing breast reconstruction, augmentation, or revision surgery.
With this addition, the Natrelle line of breast implants is the only implant line with three levels of cohesive gel. “Adding Natrelle Inspira SoftTouch breast implants to our already robust line of offerings gives Allergan the most extensive variety of implants in the industry and provides doctors with a wide range of options,” says David Nicholson, chief research and development officer of Allergan.
“Now, the Inspira line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes. We’re delighted to have this offering available in the U.S. since they are so popular with doctors and patients internationally.”
Read more at American Spa Magazine >>
 
 

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Just Digital Launches Aesthera Marketing, a Dedicated Agency for Med Spas and Aesthetic Practices
    • AI Visibility Report Details How Patients Can Find Your Brand
    • RealSelf Q1 2026 Trend Report Reveals Surge in Regenerative Aesthetics, Skin Rejuvenation
    • Biohacking Beauty: How to Elevate Aesthetic Medicine with Peptides
    • Pacific Reliance Medical M&A Advisors to Broker Sale of 21 Face to Face Medical Spa Locations